stockportfolio.pro
Stocks / CBIO vs PROK
CBIO vs PROK
Crescent Biopharma, Inc. and ProKidney Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Crescent Biopharma, Inc. (CBIO) | ProKidney Corp. (PROK) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $10.84M | $893,000 |
| Net income (latest FY) | $-153.94M | $-68.99M |
| Revenue growth (5y CAGR) | 1.3% | — |
| Net margin | -1419.6% | -7725.2% |
| Return on equity | -75.8% | 6.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CBIO — free Open PROK — freeFrequently asked questions
Which is bigger, CBIO or PROK?
Crescent Biopharma, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CBIO or PROK?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.